| 1 | discover more discover more | | | | | | | 6 | 2.26% |
| 2 | in the discovery clinical | | | | | | | 3 | 1.13% |
| 3 | of pointofcare disagnostics with | | | | | | | 2 | 0.75% |
| 4 | discovery clinical validation and | | | | | | | 2 | 0.75% |
| 5 | injuries discover more discover | | | | | | | 2 | 0.75% |
| 6 | brain injuries discover more | | | | | | | 2 | 0.75% |
| 7 | with advanced bloodbased biomarkers | | | | | | | 2 | 0.75% |
| 8 | disagnostics with advanced bloodbased | | | | | | | 2 | 0.75% |
| 9 | pointofcare disagnostics with advanced | | | | | | | 2 | 0.75% |
| 10 | mild traumatic brain injury | | | | | | | 2 | 0.75% |
| 11 | specialized in the discovery | | | | | | | 2 | 0.75% |
| 12 | the discovery clinical validation | | | | | | | 2 | 0.75% |
| 13 | recinto modernista pabellón sant | | | | | | | 1 | 0.38% |
| 14 | pau recinto modernista pabellón | | | | | | | 1 | 0.38% |
| 15 | sant pau recinto modernista | | | | | | | 1 | 0.38% |
| 16 | solution news contact selecting | | | | | | | 1 | 0.38% |
| 17 | about solution news contact | | | | | | | 1 | 0.38% |
| 18 | company specialized in the | | | | | | | 1 | 0.38% |
| 19 | commercialization of pointofcare disagnostics | | | | | | | 1 | 0.38% |
| 20 | what we do ? | | | | | | | 1 | 0.38% |
| 21 | advanced bloodbased biomarkers for | | | | | | | 1 | 0.38% |
| 22 | biomarkers for brain injuries | | | | | | | 1 | 0.38% |
| 23 | for brain injuries discover | | | | | | | 1 | 0.38% |
| 24 | more discover more who | | | | | | | 1 | 0.38% |
| 25 | modernista pabellón sant manel | | | | | | | 1 | 0.38% |
| 26 | us what we do | | | | | | | 1 | 0.38% |
| 27 | more who we are | | | | | | | 1 | 0.38% |
| 28 | a rapid access to | | | | | | | 1 | 0.38% |
| 29 | novel brain biomarkers constitute | | | | | | | 1 | 0.38% |
| 30 | brain biomarkers constitute the | | | | | | | 1 | 0.38% |
| 31 | biomarkers constitute the ip | | | | | | | 1 | 0.38% |
| 32 | constitute the ip portfolio | | | | | | | 1 | 0.38% |
| 33 | the ip portfolio of | | | | | | | 1 | 0.38% |
| 34 | c sant antoni maria | | | | | | | 1 | 0.38% |
| 35 | abcdx and allow a | | | | | | | 1 | 0.38% |
| 36 | and allow a rapid | | | | | | | 1 | 0.38% |
| 37 | allow a rapid access | | | | | | | 1 | 0.38% |
| 38 | rapid access to clinical | | | | | | | 1 | 0.38% |
| 39 | contact us what we | | | | | | | 1 | 0.38% |
| 40 | access to clinical validation | | | | | | | 1 | 0.38% |